Bibliometric analysis of levosimendan

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature Pub Date : 2025-02-01 DOI:10.1016/j.ijcha.2024.101571

Xian-Shu Zhao , Yi-Ping Yu , Yun-Tai Yao , the Evidence in Cardiovascular Anesthesia (EICA) Group

{"title":"Bibliometric analysis of levosimendan","authors":"Xian-Shu Zhao , Yi-Ping Yu , Yun-Tai Yao , the Evidence in Cardiovascular Anesthesia (EICA) Group","doi":"10.1016/j.ijcha.2024.101571","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.</div></div><div><h3>Methods</h3><div>LEVO-related publications from 1990 to 2023 were searched and retrieved in the Web of Science Core Collection (WoSCC) and analyzed with VOSviewer, CiteSpace, Scimago Graphica, R-bibliometrix and Rstudio for publication dates, countries/regions, institutions, authors, keywords, journals, and references.</div></div><div><h3>Results</h3><div>Finally, a total of 1,432 LEVO-related articles were included in the present study. Annual LEVO-related publications have been increased yearly. The United States was the most productive country with 243 articles. The University of Helsinkin published 69 articles in the field of LEVO, which were the most productive institution among all the institutions. Of all the authors, professor Pollesello,Piero was the most productive author with 62 articles. Moreover, the results of the co-citation analysis and citation bursts analysis revealed that the safety and effectiveness of LEVO were the global research trends and potential hot spots.</div></div><div><h3>Conclusions</h3><div>This study systematically summarizes the current status in the field of LEVO and provides insights into the research focuses and future hotspots.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"56 ","pages":"Article 101571"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719333/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJC Heart and Vasculature","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352906724002379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.

Methods

LEVO-related publications from 1990 to 2023 were searched and retrieved in the Web of Science Core Collection (WoSCC) and analyzed with VOSviewer, CiteSpace, Scimago Graphica, R-bibliometrix and Rstudio for publication dates, countries/regions, institutions, authors, keywords, journals, and references.

Results

Finally, a total of 1,432 LEVO-related articles were included in the present study. Annual LEVO-related publications have been increased yearly. The United States was the most productive country with 243 articles. The University of Helsinkin published 69 articles in the field of LEVO, which were the most productive institution among all the institutions. Of all the authors, professor Pollesello,Piero was the most productive author with 62 articles. Moreover, the results of the co-citation analysis and citation bursts analysis revealed that the safety and effectiveness of LEVO were the global research trends and potential hot spots.

Conclusions

This study systematically summarizes the current status in the field of LEVO and provides insights into the research focuses and future hotspots.

查看原文本刊更多论文

左西孟旦的文献计量学分析。

背景：左西孟旦（Levosimendan， LEVO）是一种钙敏化剂和三磷酸腺苷依赖性钾通道打开剂，几十年来被广泛用于内科和外科患者治疗晚期心力衰竭（HF）、右心衰、心源性休克、takotsubo心肌病、肺动脉高压等。目前，由于当前LEVO出版物的范围有限且缺乏全面的数据，因此开展需要综合信息和可量化结果的新研究的障碍越来越大。因此，本研究旨在利用文献计量学软件，识别levo相关出版物的研究趋势和热点。方法：在Web of Science Core Collection （WoSCC）中检索1990 ~ 2023年的levo相关文献，使用VOSviewer、CiteSpace、Scimago Graphica、R-bibliometrix和Rstudio等软件对出版日期、国家/地区、机构、作者、关键词、期刊和参考文献进行分析。结果：最终，本研究共纳入了1432篇与levo相关的文章。与lego相关的年度出版物逐年增加。美国是最多产的国家，有243条。赫尔辛基大学在LEVO领域发表了69篇论文，是所有机构中产出最多的机构。在所有作者中，波列塞罗教授，皮耶罗是最多产的作者，有62篇文章。此外，共被引分析和引文爆发分析结果表明，LEVO的安全性和有效性是全球研究的趋势和潜在热点。结论：本研究系统总结了LEVO领域的现状，并对研究重点和未来热点提出了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

IJC Heart and Vasculature Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.90

自引率

10.30%

发文量

216

审稿时长

56 days

期刊介绍： IJC Heart & Vasculature is an online-only, open-access journal dedicated to publishing original articles and reviews (also Editorials and Letters to the Editor) which report on structural and functional cardiovascular pathology, with an emphasis on imaging and disease pathophysiology. Articles must be authentic, educational, clinically relevant, and original in their content and scientific approach. IJC Heart & Vasculature requires the highest standards of scientific integrity in order to promote reliable, reproducible and verifiable research findings. All authors are advised to consult the Principles of Ethical Publishing in the International Journal of Cardiology before submitting a manuscript. Submission of a manuscript to this journal gives the publisher the right to publish that paper if it is accepted. Manuscripts may be edited to improve clarity and expression.